VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided study

Billingham, Lucinda (Researcher)
Freeman, Sylvie (Co-Investigator)
Craddock, Charles (Principal Investigator)

Cancer Research UK Clinical Trials Unit

Short title	VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided study
Status	Active
Effective start/end date	1/02/20 → 31/12/28

Funding

Cancer Research UK
Abbvie Ltd

Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML
Russell, N., Othman, J., Cumming, O., Thomas, A., Tedjaseputra, A., Potter, N., Jovanovic, J., Gilkes, A., Batten, L., Canham, J., Hinson, E., Runglall, M., Aucken, P., Kottaridis, P., Cavenagh, J., Arnold, C., Freeman, S., Dennis, M., Knapper, S. & Dillon, R., 23 Dec 2025, In: Blood Advances. 9, 24, p. 6455-6466 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
3 Downloads (Pure)